Clinical Trials Logo

Malignant Neoplasm clinical trials

View clinical trials related to Malignant Neoplasm.

Filter by:

NCT ID: NCT03219502 Active, not recruiting - Malignant Neoplasm Clinical Trials

rTMS in Improving Neuropathy in Patients With Stage I-IV Cancer Who Have Received Oxaliplatin Chemotherapy

Start date: July 10, 2017
Phase: N/A
Study type: Interventional

This trial studies how well repetitive transcranial magnetic stimulation (rTMS) works in improving neuropathy due to oxaliplatin chemotherapy in patients with stage I-IV cancer. rTMS is designed to change brain activity by introducing small magnetic impulses to the scalp that encourage the brain to change its activity.

NCT ID: NCT02988271 Active, not recruiting - Depression Clinical Trials

Meditation Therapy in Improving Anxiety and Depression in Cancer Patients With Psychosocial Distress

Start date: April 11, 2019
Phase: N/A
Study type: Interventional

This trial studies how well self-administered meditation therapy works in improving anxiety and depression in cancer patients who exhibit psychosocial distress. Meditation therapy is a mind-body approach that uses a variety of techniques, such as deep breathing, sound, or movement, that may help to decrease distress and anxiety and enhance the health and quality of life of patients with cancer.

NCT ID: NCT02860039 Active, not recruiting - Influenza Clinical Trials

High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant

Start date: September 2016
Phase: Phase 2
Study type: Interventional

This phase II randomized trial studies how well high dose flu vaccine works in treating children who have undergone done stem cell transplant. Higher dose flu vaccine may build a better immune response and may provide better protection against the flu than the standard vaccine.

NCT ID: NCT02598726 Active, not recruiting - Pain Clinical Trials

Curcumin and Piperine in Reducing Inflammation for Ureteral Stent-Induced Symptoms in Patients With Cancer

Start date: March 1, 2016
Phase: Phase 1
Study type: Interventional

This pilot phase I trial studies the side effects and best dose of curcumin when given together with piperine (piperine extract [standardized]) in reducing inflammation for ureteral stent-induced symptoms in patients with cancer. Curcumin is a spice similar to turmeric and works by decreasing the chemical moderators that produce inflammation in the body. Piperine is pepper and works by increasing the amount of curcumin available in the body when taken with curcumin. Giving curcumin together with piperine may reduce inflammation and discomfort from a ureteric stent in older patients with cancer.

NCT ID: NCT02566304 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Start date: November 13, 2015
Phase: Phase 2
Study type: Interventional

This clinical trial studies the use of reduced intensity chemotherapy and radiation therapy before donor stem cell transplant in treating patients with hematologic malignancies. Giving low doses of chemotherapy, such as cyclophosphamide and fludarabine phosphate, before a donor stem cell transplant may help stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Reducing the intensity of the chemotherapy and radiation may also reduce the side effects of the donor stem cell transplant.

NCT ID: NCT02408406 Active, not recruiting - Breast Carcinoma Clinical Trials

PatientCareAnywhere Internet-Based Software in Improving Communication and Education in Patients With Cancer and Their Healthcare Providers

Start date: July 7, 2015
Phase: N/A
Study type: Interventional

This partially randomized pilot clinical trial develops and studies a software program, called PatientCareAnywhere, to see whether it can help patients communicate with their doctors and other healthcare providers, and educate themselves about their cancer and treatment options. A program that can help patients learn about their cancer and treatment options, and allows the patient's healthcare providers to receive their questionnaire results, may help patients identify and get help to treat their symptoms.

NCT ID: NCT02357134 Active, not recruiting - Dyspnea Clinical Trials

High-Flow Oxygen in Reducing Shortness of Breath Caused by Exercise in Patients With Cancer

Start date: March 17, 2015
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well high-flow oxygen works in reducing difficulty breathing during exercise (exertional dyspnea) in patients with cancer. Dyspnea is linked to decreased lung function, quality of life, and survival. High-flow oxygen is a device that delivers heated and humidified oxygen through the nose. This may be effective in reducing dyspnea, and may help patients' lungs function better and improve their quality of life.

NCT ID: NCT02337452 Active, not recruiting - Malignant Neoplasm Clinical Trials

Web-Based Family Outreach Program for Cancer Prevention in High-Risk Families

Start date: April 10, 2015
Phase:
Study type: Observational

This trial develops a patient-driven self-navigated web-based family outreach program for cancer prevention in high-risk families. Creating the family outreach program may help to improve the way in which genetic test results are communicated within families and increase the number of at-risk relatives who become aware of their risks.

NCT ID: NCT02272998 Active, not recruiting - Malignant Neoplasm Clinical Trials

Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.

Start date: February 24, 2015
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well ponatinib hydrochloride works in treating patients with cancer that has spread to other parts of the body (metastatic), has failed previous treatment (refractory), and has one of several alterations, or mutations, in its deoxyribonucleic acid (DNA) sequence. Ponatinib hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether a patient's genetic alterations may affect how well ponatinib hydrochloride works.

NCT ID: NCT02243592 Active, not recruiting - Malignant Neoplasm Clinical Trials

Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment

Start date: September 24, 2014
Phase:
Study type: Observational

This pilot research trial studies molecular profiling in tissue samples from patients with cancer who got better with treatment that didn't work for most other patients with the same disease. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to how well patients respond to treatment.